You are here

  • Home
  • Archive
  • Volume 33, Issue 11
  • Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England

Article metrics

Article menu
Original research
Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England

 

Online download statistics by month:

Online download statistics by month: August 2023 to October 2024

AbstractFullPdf
Aug 202323122255
Sep 202326525964
Oct 202329329457
Nov 2023478472122
Dec 202329629783
Jan 202428027861
Feb 202420019459
Mar 202413413380
Apr 202410410456
May 2024848234
Jun 20241039446
Jul 202410210360
Aug 2024555329
Sep 2024777639
Oct 2024332
Total27052664847